Treatment of COVID-19: old tricks for new challenges.

Published on Mar 16, 2020in Critical Care6.959
· DOI :10.1186/S13054-020-2818-6
Anne Cunningham12
Estimated H-index: 12
(UBD: Universiti Brunei Darussalam),
Hui Poh Goh2
Estimated H-index: 2
(UBD: Universiti Brunei Darussalam),
David Koh43
Estimated H-index: 43
(NUS: National University of Singapore)
  • References (8)
  • Citations (29)
📖 Papers frequently viewed together
2,504 Citations
550 Citations
35 Citations
78% of Scinapse members use related papers. After signing in, all features are FREE.
#1Jianjun Gao (Qingdao University)H-Index: 15
#2Zhenxue TianH-Index: 1
Last. Xu YangH-Index: 1
view all 3 authors...
The coronavirus disease 2019 (COVID-19) virus is spreading rapidly, andscientists are endeavoring to discover drugs for its efficacious treatment inChina. Chloroquine phosphate, an old drug for treatment of malaria, is shown tohave apparent efficacy and acceptable safety against COVID-19 associatedpneumonia in multicenter clinical trials conducted in China. The drug isrecommended to be included in the next version of the Guidelines for thePrevention, Diagnosis, and Treatment of Pneumonia Caused ...
403 CitationsSource
#1Yong LiuH-Index: 1
#2Jinxiu LiH-Index: 1
Last. Yongwen FengH-Index: 1
view all 3 authors...
11 CitationsSource
#1Hui Luo (Beijing University of Chinese Medicine)H-Index: 1
#1Hubin LuoH-Index: 2
Last. Jianping Liu (Beijing University of Chinese Medicine)H-Index: 35
view all 7 authors...
Objective: Since December 2019, an outbreak of corona virus disease 2019 (COVID-19) occurred in Wuhan, and rapidly spread to almost all parts of China. This was followed by prevention programs recommending Chinese medicine (CM) for the prevention. In order to provide evidence for CM recommendations, we reviewed ancient classics and human studies. Methods: Historical records on prevention and treatment of infections in CM classics, clinical evidence of CM on the prevention of severe acute respira...
51 CitationsSource
#1Chih Cheng LaiH-Index: 6
#1Chih-Cheng LaiH-Index: 23
Last. Po-Ren Hsueh (NTU: National Taiwan University)H-Index: 72
view all 5 authors...
ABSTRACT Emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, previously provisionally named 2019 novel coronavirus or 2019-nCoV) disease (COVID-19) in China at the end of 2019, has caused a large global outbreak and a major public health issue. As of February 11, 2020, data from the WHO has shown that more than 43,000 confirmed cases have been identified in 28 countries/regions, with more than 99% of the cases being detected in China. On January 30, 2020, WHO has declared C...
409 CitationsSource
#1Yaseen M. ArabiH-Index: 49
#2Ali H. HajeerH-Index: 47
Last. Mashail AlahmadiH-Index: 1
view all 19 authors...
We explored the feasibility of collecting convalescent plasma for passive immunotherapy of Middle East respiratory syndrome coronavirus (MERS-CoV) infection by using ELISA to screen serum samples from 443 potential plasma donors: 196 patients with suspected or laboratory-confirmed MERS-CoV infection, 230 healthcare workers, and 17 household contacts exposed to MERS-CoV. ELISA-reactive samples were further tested by indirect fluorescent antibody and microneutralization assays. Of the 443 tested s...
20 CitationsSource
#1Giuseppe Marano (ISS: Istituto Superiore di Sanità)H-Index: 25
#2Stefania VaglioH-Index: 7
Last. Giuliano Grazzini (ISS: Istituto Superiore di Sanità)H-Index: 14
view all 7 authors...
Passive immunisation for the prevention and treatment of human infectious diseases can be traced back to the 20th century. The recent Ebola virus outbreak in West Africa has turned the spotlight onto the possible use of convalescent whole blood and convalescent plasma in the treatment of infectious diseases because they are the only therapeutic strategy available in some cases, given the unavailability of vaccines, drugs or other specific treatments. Convalescent blood products could be a valid ...
10 CitationsSource
#1John Mair-Jenkins (PHE: Public Health England)H-Index: 4
#2Maria Saavedra-Campos (PHE: Public Health England)H-Index: 5
Last. Yingjie Feng JenkinsH-Index: 1
view all 22 authors...
Background. Administration of convalescent plasma, serum, or hyperimmune immunoglobulin may be of clinical benefit for treatment of severe acute respiratory infections (SARIs) of viral etiology. We conducted a systematic review and exploratory meta-analysis to assess the overall evidence. Methods. Healthcare databases and sources of grey literature were searched in July 2013. All records were screened against the protocol eligibility criteria, using a 3-stage process. Data extraction and risk of...
88 CitationsSource
#1Mikhail Menis (CBER: Center for Biologics Evaluation and Research)H-Index: 7
#2Gayathri SridharH-Index: 6
Last. Hector S. Izurieta (CBER: Center for Biologics Evaluation and Research)H-Index: 26
view all 12 authors...
Thrombotic events (TEs) are rare serious complications following administration of hyperimmune globulin (HIG) products. Our retrospective claims-based study assessed occurrence of same-day TEs following administration of HIGs during 2008–2011 and examined potential risk factors using HealthCore's Integrated Research Database (HIRDSM) and laboratory testing of products' procoagulant Factor XIa activity by U.S. Food and Drug Administration. Multivariable regression was used to estimate same-day TE...
16 CitationsSource
Cited By29
#1Jaume Alijotas-Reig (Autonomous University of Barcelona)H-Index: 17
Last. Francesc Miró-MurH-Index: 5
view all 9 authors...
Abstract Severe Acute Respiratory Syndrome related to Coronavirus-2 (SARS-CoV-2), coronavirus disease-2019 (COVID-19) may cause severe illness in 20% of patients. This may be in part due to an uncontrolled immune-response to SARS-CoV-2 infection triggering a systemic hyperinflammatory response, the so-called “cytokine storm”. The reduction of this inflammatory immune-response could be considered as a potential therapeutic target against severe COVID-19. The relationship between inflammation and ...
4 CitationsSource
#1O. S. AlbahriH-Index: 12
#2Jameel R. Al-Obaidi (UPSI: Sultan Idris University of Education)H-Index: 1
Last. Karrar Hameed Abdulkareem (UTHM: Universiti Tun Hussein Onn Malaysia)H-Index: 1
view all 14 authors...
Abstract Context People who have recently recovered from the threat of deteriorating coronavirus disease-2019 (COVID-19) have antibodies to the coronavirus circulating in their blood. Thus, the transfusion of these antibodies to deteriorating patients could theoretically help boost their immune system. Biologically, two challenges need to be surmounted to allow convalescent plasma (CP) transfusion to rescue the most severe COVID-19 patients. First, convalescent subjects must meet donor selection...
#1Linzi Fan (HMU: Harbin Medical University)
#2Shuang Jiang (HMU: Harbin Medical University)
Last. Chunjuan Yang (HMU: Harbin Medical University)H-Index: 6
view all 5 authors...
An unprecedented outbreak of the novel coronavirus in China (COVID-19) occurred in December 2019, and then engulfed the entire world, presenting a significant and urgent threat to global health. Many research institutes have been involved in the development of drugs and vaccines against COVID-19. At present, the strategy of new use of old drugs is mainly used to screen candidate drugs against the novel coronavirus (later termed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)) and in...
#1Michael R. ShurinH-Index: 45
Last. Sarah E. WheelerH-Index: 17
view all 4 authors...
#1Serena Tharakan (ISMMS: Icahn School of Medicine at Mount Sinai)H-Index: 1
#2Koichi Nomoto (ISMMS: Icahn School of Medicine at Mount Sinai)H-Index: 5
Last. Kiyotake Ishikawa (ISMMS: Icahn School of Medicine at Mount Sinai)H-Index: 21
view all 4 authors...
#1Amir-Hadi Maghzi (Brigham and Women's Hospital)H-Index: 19
#2Maria K. Houtchens (Brigham and Women's Hospital)H-Index: 17
Last. Tamara H. W. Schwartz (Maine Medical Center)H-Index: 1
view all 15 authors...
The outbreak of a severe acute respiratory syndrome caused by a novel coronavirus (COVID-19), has raised health concerns for patients with multiple sclerosis (MS) who are commonly on long-term immunotherapies. Managing MS during the pandemic remains challenging with little published experience and no evidence-based guidelines. We present five teriflunomide-treated patients with MS who subsequently developed active COVID-19 infection. The patients continued teriflunomide therapy and had self-limi...
1 CitationsSource
#1Xiangxi Wang (CAS: Chinese Academy of Sciences)H-Index: 14
#2Yong-Qiang Deng (Academy of Military Medical Sciences)H-Index: 3
Last. Yao Sun (CAS: Chinese Academy of Sciences)H-Index: 17
view all 23 authors...
The COVID-19 pandemic caused by the SARS-CoV-2 virus has resulted in an unprecedented public health crisis. There are no approved vaccines or therapeutics for treating COVID-19. Here we reported a humanized monoclonal antibody, H014, efficiently neutralizes SARS-CoV-2 and SARS-CoV pseudoviruses as well as authentic SARS-CoV-2 at nM level by engaging the S receptor binding domain (RBD). Importantly, H014 administration reduced SARS-CoV-2 replication and prevented pulmonary pathology in hACE2 mous...
1 CitationsSource
#1Ziad A. Ali (University of Louisville)
#2Rif S. El-Mallakh (University of Louisville)H-Index: 33
Abstract Coronavirus Diseases-2019 (COVID-19) has caused a large global outbreak and has been declared as a pandemic by the World Health Organization (WHO). It has been proposed that COVID-19-related hyperinflammation and dysregulated immune response might play a critical role in developing a cytokine storm which usually progresses to a life-threatening acute lung injury or acute respiratory distress syndrome in infected individuals. Lidocaine, a local analgesic and anti-arrhythmic, is known for...
#1Shuvasish Choudhury (Assam University)H-Index: 10
#2Debojyoti Moulick (Assam University)H-Index: 1
Last. Muhammed Khairujjaman Mazumder (Dhemaji College)H-Index: 1
view all 4 authors...
Abstract Background Coronavirus disease 2019 (COVID-19) has already affected 2883603 and killed 198842 people, as of April 27, 2020. Because there is no specific therapeutic drug, drug repurposing has been proposed. RNA-dependent RNA polymerase (RdRp) is a promising drug against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to control its replication, and several compounds have been suggested. The present study predicts relative efficacies of thirty known or repurposed compounds i...
#1Ivan F. N. Hung (HKU: University of Hong Kong)H-Index: 39
#2Kwok-Cheung Lung (Pamela Youde Nethersole Eastern Hospital)H-Index: 1
Last. Anthony Raymond Tam (HKU: University of Hong Kong)H-Index: 2
view all 44 authors...
Summary Background Effective antiviral therapy is important for tackling the coronavirus disease 2019 (COVID-19) pandemic. We assessed the efficacy and safety of combined interferon beta-1b, lopinavir–ritonavir, and ribavirin for treating patients with COVID-19. Methods This was a multicentre, prospective, open-label, randomised, phase 2 trial in adults with COVID-19 who were admitted to six hospitals in Hong Kong. Patients were randomly assigned (2:1) to a 14-day combination of lopinavir 400 mg...
27 CitationsSource